ヒドロモルフォン (Japanese Wikipedia)

“Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers”. Anesth. Analg. 97 (1): 117–23, table of contents. (July 2003). doi:10.1213/01.ANE.0000066311.40978.4F. PMID 12818953.
“Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects”. J Clin Pharmacol 21 (4): 152–6. (April 1981). doi:10.1002/j.1552-4604.1981.tb05693.x. PMID 6165742.
Tuohy, N; Paparella, S (December 2005). “Look-alike and sound-alike drugs: errors just waiting to happen”. J Emerg Nurs 31 (6): 569–71. doi:10.1016/j.jen.2005.07.012. PMID 16308048.
Brennan, MJ (2013). “The effect of opioid therapy on endocrine function”. The American Journal of Medicine 126 (3 Suppl 1): S12–8. doi:10.1016/j.amjmed.2012.12.001. PMID 23414717.
Thwaites, D; McCann, S; Broderick, P (Aug 2004). “Hydromorphone neuroexcitation.”. Journal of Palliative Medicine 7 (4): 545–50. doi:10.1089/1096621041838362. PMID 15353098.
Gagnon, DJ; Jwo, K (2013). “Tremors and agitation following low-dose intravenous hydromorphone administration in a patient with kidney dysfunction”. Annals of Pharmacotherapy 47 (7–8): e34. doi:10.1345/aph.1R784. PMID 23715067.
Rapp, SE; Egan, KJ; Ross, BK; Wild, LM; Terman, GW; Ching, JM (May 1996). “A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia.”. Anesth. Analg. 82 (5): 1043–8. doi:10.1213/00000539-199605000-00029. PMID 8610865.
“Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors”. Bioorg. Med. Chem. 9 (1): 69–76. (January 2001). doi:10.1016/S0968-0896(00)00223-6. PMID 11197347.
Sarhill, Nabeel; Walsh, Declan; Nelson, Kristine A. (9 February 2014). “Hydromorphone: pharmacology and clinical applications in cancer patients”. Supportive Care in Cancer 9 (2): 84–96. doi:10.1007/s005200000183. ISSN 0941-4355.
Gregory, Thomas B. (2013). “Hydromorphone: Evolving to Meet the Challenges of Today's Health Care Environment”. Clinical Therapeutics 35 (12): 2007–2027. doi:10.1016/j.clinthera.2013.09.027. PMID 24290733.

drugs.com

“Hydromorphone – FDA prescribing information, side effects and uses”. drugs.com. 2 September 2017閲覧。
“Drug interactions between Dilaudid and Valium”. 19 November 2014閲覧。

fda.gov

accessdata.fda.gov

“DILAUDID® ORAL LIQUID and DILAUDID® TABLETS Package Insert”. FDA (2007年). 5 November 2015閲覧。
“EXALGO (hydromorphone hydrochloride) extended release tablets Package Insert”. FDA (2010年). 5 November 2015閲覧。

google.ca

books.google.ca

Fischer, Jnos; Ganellin, C. Robin (2006) (英語). Analogue-based Drug Discovery. John Wiley & Sons. p. 526. ISBN 9783527607495

mcmaster.ca

nationalpaincentre.mcmaster.ca

“Switching Opioids”. mcmaster.ca. 2 September 2017閲覧。

medscape.com

emedicine.medscape.com

Withdrawal Syndromes: Practice Essentials, Background, Pathophysiology. (2019-02-05).

narconon.org

“Hydromorphone Drug Information”. Narconon International. 5 November 2015閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

“Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers”. Anesth. Analg. 97 (1): 117–23, table of contents. (July 2003). doi:10.1213/01.ANE.0000066311.40978.4F. PMID 12818953.
“Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects”. J Clin Pharmacol 21 (4): 152–6. (April 1981). doi:10.1002/j.1552-4604.1981.tb05693.x. PMID 6165742.
Cohen, MR (June 1992). “Doctor was thinking of the wrong drug”. Nursing 22 (6): 25. PMID 1377371.
Tuohy, N; Paparella, S (December 2005). “Look-alike and sound-alike drugs: errors just waiting to happen”. J Emerg Nurs 31 (6): 569–71. doi:10.1016/j.jen.2005.07.012. PMID 16308048.
Brennan, MJ (2013). “The effect of opioid therapy on endocrine function”. The American Journal of Medicine 126 (3 Suppl 1): S12–8. doi:10.1016/j.amjmed.2012.12.001. PMID 23414717.
Thwaites, D; McCann, S; Broderick, P (Aug 2004). “Hydromorphone neuroexcitation.”. Journal of Palliative Medicine 7 (4): 545–50. doi:10.1089/1096621041838362. PMID 15353098.
Gagnon, DJ; Jwo, K (2013). “Tremors and agitation following low-dose intravenous hydromorphone administration in a patient with kidney dysfunction”. Annals of Pharmacotherapy 47 (7–8): e34. doi:10.1345/aph.1R784. PMID 23715067.
Rapp, SE; Egan, KJ; Ross, BK; Wild, LM; Terman, GW; Ching, JM (May 1996). “A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia.”. Anesth. Analg. 82 (5): 1043–8. doi:10.1213/00000539-199605000-00029. PMID 8610865.
Bell CC (1983). “Simultaneous treatment of hypertension and opiate withdrawal using an alpha 2 adrenergic agonist”. J Natl Med Assoc 75 (1): 89–93. PMC 2561435. PMID 6131140.
“Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors”. Bioorg. Med. Chem. 9 (1): 69–76. (January 2001). doi:10.1016/S0968-0896(00)00223-6. PMID 11197347.
Nersesyan, Hrachya; Slavin, Konstantin V (1 June 2007). “Current aproach〔ママ〕 to cancer pain management: Availability and implications of different treatment options”. Therapeutics and Clinical Risk Management 3 (3): 381–400. ISSN 1176-6336. PMC 2386360. PMID 18488078.
Knight, Karen H. (Feb 2007). “Implantable Intrathecal Pumps for Chronic Pain: Highlights and Updates”. Croatian Medical Journal 48 (1): 22–34. PMC 2080496. PMID 17309136.
Gregory, Thomas B. (2013). “Hydromorphone: Evolving to Meet the Challenges of Today's Health Care Environment”. Clinical Therapeutics 35 (12): 2007–2027. doi:10.1016/j.clinthera.2013.09.027. PMID 24290733.

ncbi.nlm.nih.gov

Treatment, Center for Substance Abuse (1 January 2004). 4 Treatment Protocols. Substance Abuse and Mental Health Services Administration (US).
Bell CC (1983). “Simultaneous treatment of hypertension and opiate withdrawal using an alpha 2 adrenergic agonist”. J Natl Med Assoc 75 (1): 89–93. PMC 2561435. PMID 6131140.
Nersesyan, Hrachya; Slavin, Konstantin V (1 June 2007). “Current aproach〔ママ〕 to cancer pain management: Availability and implications of different treatment options”. Therapeutics and Clinical Risk Management 3 (3): 381–400. ISSN 1176-6336. PMC 2386360. PMID 18488078.
Knight, Karen H. (Feb 2007). “Implantable Intrathecal Pumps for Chronic Pain: Highlights and Updates”. Croatian Medical Journal 48 (1): 22–34. PMC 2080496. PMID 17309136.

pmc.ncbi.nlm.nih.gov

Bell CC (1983). “Simultaneous treatment of hypertension and opiate withdrawal using an alpha 2 adrenergic agonist”. J Natl Med Assoc 75 (1): 89–93. PMC 2561435. PMID 6131140.
Nersesyan, Hrachya; Slavin, Konstantin V (1 June 2007). “Current aproach〔ママ〕 to cancer pain management: Availability and implications of different treatment options”. Therapeutics and Clinical Risk Management 3 (3): 381–400. ISSN 1176-6336. PMC 2386360. PMID 18488078.
Knight, Karen H. (Feb 2007). “Implantable Intrathecal Pumps for Chronic Pain: Highlights and Updates”. Croatian Medical Journal 48 (1): 22–34. PMC 2080496. PMID 17309136.

nii.ac.jp

ci.nii.ac.jp

細川貴史「ナルラピド^®錠1mg, 2mg, 4mg／ナルサス^®錠2mg, 6mg, 12mg, 24mg」『ファルマシア』第53巻第9号、日本薬学会、2017年9月1日、NAID 130006038577。

painweek.org

http://www.painweek.org/../292-50.pdf

purduepharma.com

Hydromorphone Hydrochloride; MSDS No. 71681; Purdue Pharma L.P.: Stamford, CT, 13 October 2009. http://www.purduepharma.com/msdss/Dilaudid_2_4_8mgTablets_OralLiquid_MSDS.pdf (accessed November 5, 2015) Archived 17 January 2015 at the Wayback Machine.

app.purduepharma.com

“Dilaudid (hydromorphone hydrochloride) Oral LiquidDilaudid (hydromorphone hydrochloride) Tablets”. app.purduepharma.com. 5 November 2015閲覧。

rapiddrugdetox.com

“Hydromorphone / Dilaudid Detox” (英語). Rapid Drug Detox. 5 November 2015閲覧。

rxlist.com

Hydromorphone Monograph Archived 13 February 2008 at the Wayback Machine. (Side Effects & Drug Interactions)
“Dilaudid Clinical Pharmacology”. rxlist.com. 12 June 2008時点のオリジナルよりアーカイブ。2 September 2017閲覧。

saskatoonhealthregion.ca

“Opioid withdrawal protocol”. www.saskatoonhealthregion.ca. 25 November 2015時点のオリジナルよりアーカイブ。5 November 2015閲覧。

thatspoppycock.com

“Hydromorphone”. That's Poppycock! (19 February 2009). 2019年3月25日閲覧。

virginia.edu

medicine.virginia.edu

Buck (July 2008). “Use of Hydromorphone in Children and Adolescents”. University of Virginia Children's Hospital. 5 November 2015閲覧。

web.archive.org

Hydromorphone Hydrochloride; MSDS No. 71681; Purdue Pharma L.P.: Stamford, CT, 13 October 2009. http://www.purduepharma.com/msdss/Dilaudid_2_4_8mgTablets_OralLiquid_MSDS.pdf (accessed November 5, 2015) Archived 17 January 2015 at the Wayback Machine.
Hydromorphone Monograph Archived 13 February 2008 at the Wayback Machine. (Side Effects & Drug Interactions)
“Opioid withdrawal protocol”. www.saskatoonhealthregion.ca. 25 November 2015時点のオリジナルよりアーカイブ。5 November 2015閲覧。
“Opioid Conversion Guidelines”. alfredhealth.org.au. 4 March 2016時点のオリジナルよりアーカイブ。2 September 2017閲覧。
“Dilaudid Clinical Pharmacology”. rxlist.com. 12 June 2008時点のオリジナルよりアーカイブ。2 September 2017閲覧。
PHA 4220 – Neurology Pharmacotherapeutics Archived 16 July 2007 at the Wayback Machine.

webmd.com

Palladoneの鎮痛剤が市場から流出

worldcat.org

search.worldcat.org

Nersesyan, Hrachya; Slavin, Konstantin V (1 June 2007). “Current aproach〔ママ〕 to cancer pain management: Availability and implications of different treatment options”. Therapeutics and Clinical Risk Management 3 (3): 381–400. ISSN 1176-6336. PMC 2386360. PMID 18488078.
Sarhill, Nabeel; Walsh, Declan; Nelson, Kristine A. (9 February 2014). “Hydromorphone: pharmacology and clinical applications in cancer patients”. Supportive Care in Cancer 9 (2): 84–96. doi:10.1007/s005200000183. ISSN 0941-4355.

zalicus.com

“zalicus.com”. www.zalicus.com. 2 September 2017閲覧。